These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 25070547

  • 1. Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial.
    Edelman AB, Cherala G, Munar MY, McInnis M, Stanczyk FZ, Jensen JT.
    Contraception; 2014 Nov; 90(5):550-6. PubMed ID: 25070547
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. An investigation into the effect of tenidap sodium on the pharmacokinetics of a combined oral contraceptive.
    Coates PE, Mesure R.
    Br J Clin Pharmacol; 1995 Nov; 39 Suppl 1(Suppl 1):47S-50S. PubMed ID: 7547095
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation.
    Kuhnz W, al-Yacoub G, Fuhrmeister A.
    Contraception; 1992 Nov; 46(5):455-69. PubMed ID: 1458892
    [Abstract] [Full Text] [Related]

  • 8. Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers.
    Macha S, Mattheus M, Pinnetti S, Woerle HJ, Broedl UC.
    Clin Drug Investig; 2013 May; 33(5):351-7. PubMed ID: 23512637
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study.
    Taekema-Roelvink ME, Swart PJ, Kuipers ME, Krauwinkel WJ, Visser N, Smulders RA.
    Clin Ther; 2005 Sep; 27(9):1403-10. PubMed ID: 16291413
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity.
    Edelman AB, Carlson NE, Cherala G, Munar MY, Stouffer RL, Cameron JL, Stanczyk FZ, Jensen JT.
    Contraception; 2009 Aug; 80(2):119-27. PubMed ID: 19631786
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study.
    Johnson-Agbakwu C, Brown L, Yuan J, Kissling R, Greenblatt DJ.
    Clin Ther; 2018 Jan; 40(1):64-73. PubMed ID: 29198449
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers.
    Cawello W, Rosenkranz B, Schmid B, Wierich W.
    Epilepsia; 2013 Mar; 54(3):530-6. PubMed ID: 23360419
    [Abstract] [Full Text] [Related]

  • 16. Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers.
    Sabo JP, Lang B, Elgadi M, Huang F.
    Antimicrob Agents Chemother; 2015 Jan; 59(1):514-9. PubMed ID: 25385099
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of a triphasic oral contraceptive containing desogestrel and ethinyl estradiol.
    Archer DF, Timmer CJ, Lammers P.
    Fertil Steril; 1994 Apr; 61(4):645-51. PubMed ID: 8150105
    [Abstract] [Full Text] [Related]

  • 18. Effects of ritonavir-boosted protease inhibitors on combined oral contraceptive pharmacokinetics and pharmacodynamics in HIV-positive women.
    Barcellos T, Natavio M, Stanczyk FZ, Luo D, Jusko WJ, Bender NM.
    Contraception; 2019 Oct; 100(4):283-287. PubMed ID: 31194965
    [Abstract] [Full Text] [Related]

  • 19. Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants.
    Devineni D, Manitpisitkul P, Vaccaro N, Bernard A, Skee D, Mamidi RN, Tian H, Weiner S, Stieltjes H, Sha S, Rothenberg P.
    Int J Clin Pharmacol Ther; 2015 Jan; 53(1):41-53. PubMed ID: 25345427
    [Abstract] [Full Text] [Related]

  • 20. No clinically relevant drug-drug interactions when dalcetrapib is co-administered with a monophasic oral contraceptive (Microgynon® 30).
    Young A, Anzures-Cabrera J, Derks M.
    Int J Clin Pharmacol Ther; 2012 Apr; 50(4):248-56. PubMed ID: 22456295
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.